THE Cathay Drug CO. Inc Pharmaceutical Import Profile — Philippines (DGFT 2022–2026)

Name: THE Cathay Drug CO. Inc Pharmaceutical Import Records from India — 2 Products, $1.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

THE Cathay Drug CO. Inc — Pharmaceutical Importer Profile (2026) | 2 Products, $1.4M Trade | TransData Nexus

THE Cathay Drug CO. Inc

Pharmaceutical Importer · Philippines · Antihistamines & Allergy Focus · $1.4M Total Trade · DGFT Verified

THE Cathay Drug CO. Inc is a pharmaceutical importer based in Philippines with a total trade value of $1.4M across 2 products in 2 therapeutic categories. Based on 28 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. THE Cathay Drug CO. Inc sources from 1 verified Indian supplier, with Ajanta Pharma Limited accounting for 100.0% of imports.

THE Cathay Drug CO. Inc — Import Portfolio & Supplier Network

THE Cathay Drug CO. Inc import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to THE Cathay Drug CO. Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Ajanta Pharma Limited	$1.9M	66	100.0%

THE Cathay Drug CO. Inc sources from 1 verified Indian supplier across 38 distinct formulations. The sourcing is highly concentrated — Ajanta Pharma Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does THE Cathay Drug CO. Inc Import?

Formulation	Value	Ships
Zykast TAB 10/5MG[123549pac x 3 x 10 = 3706470][montelukast 10 MG plus levocetirizine 5 MG	$150.0K	3
Zykast TAB 10/5MG[187104 x 3 x 10 = 5613120][montelukast 10 MG plus levocetirizine 5 MG tablets]cont:as per	$150.0K	3
Dilatair 200MG tablets[76848 x 3 x 10 =2305440 tablets][Each uncoated tablet contains:doxofylline	$148.0K	3
Dilatair 400MG tablets[38622x3x10=1158660 tabs][doxofylline tablets 400MG][eachuncoated tablet conts:doxofylline	$135.4K	3
Dilatair 200MG tablets[51407 x 3 x 10 =1542210 tablets]][Each uncoated tablet contains:doxofylline	$114.6K	3
Zykids forte TAB 5/5MG[25680packx3x10=770400 tabs]Each chewable TAB cont:montelukast sodium USP 5.2 MG as per	$90.5K	3
Zykids forte TAB 5/5MG[19280packx3x10=578400tabs]Each chewable tablet contains :montelukast sodium USP 5.2 MG as per	$67.8K	3
Dilatair 200MG tablets[51359pac x 3 x	$50.0K	1
Dilatair 200MG tablets [51801 x 3 x 10	$50.0K	1
Dilatair 400MG tablets [23821 x 3 x 10	$50.0K	1
Zykast 10/5 MG tablets[251846 x 3 x 10	$50.0K	1
Zykast 10/5 MG tablets[48751pac x 3 x	$50.0K	1
Zykast 10/5 MG tablets[128775pacx3x10=38	$50.0K	1
Zykast 10/5 MG tablets[96714pacx3x10=290	$50.0K	1
Dilatair 400MG tablets[25301pac x 3 x	$50.0K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Cetirizine	Antihistamines & Allergy	$700.0K	14	0.3%	3
2	Montelukast	Respiratory	$700.0K	14	0.3%	5

THE Cathay Drug CO. Inc imports 2 pharmaceutical products across 2 categories into Philippines totaling $1.4M.

THE Cathay Drug CO. Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

The Cathay Drug Company, Inc. (CDCI) is a privately held Filipino pharmaceutical firm established in 1952 by the family of Yao Shiong Shio. Headquartered at 2/F Vernida I Condominium, 120 Amorsolo Street, Legaspi Village, Makati City, Metro Manila, Philippines, CDCI specializes in the marketing and distribution of pharmaceutical and animal health products.

Historically, from 1952 to 2000, CDCI served as the exclusive distributor for Merck Sharp & Dohme (MSD) in the Philippines, handling both human and animal health products. Over the decades, the company has diversified its portfolio by entering into licensing agreements with various international and domestic pharmaceutical manufacturers, including Ajanta Pharma Ltd. (India), Lupin Ltd. (India), Aurobindo Pharma Ltd. (India), Zambon SpA (Italy), and Biopharm Chemicals Co. Ltd. (Thailand).

CDCI's role in the Philippine pharmaceutical distribution network is significant, as it bridges international manufacturers with the local market, ensuring the availability of a diverse range of pharmaceutical products to meet the country's healthcare needs.

2Distribution Network

While specific details about CDCI's warehouse locations and logistics capabilities are not publicly disclosed, the company's extensive distribution network is evident through its partnerships with multiple international and domestic pharmaceutical manufacturers. This network enables CDCI to effectively supply a wide array of pharmaceutical products across the Philippines. The company's strategic location in Makati City, a central business district, further facilitates efficient distribution and logistics operations.

3Industry Role

CDCI operates primarily as a pharmaceutical importer and distributor within the Philippine market. By sourcing products from various international manufacturers, including those in India, and distributing them locally, CDCI plays a crucial role in ensuring the availability of diverse pharmaceutical products to meet the healthcare needs of the Filipino population.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — THE Cathay Drug CO. Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

CDCI's sourcing strategy reveals a notable concentration on a single supplier, Ajanta Pharma Ltd. of India, which accounts for 100% of the company's pharmaceutical imports from India. This exclusive sourcing arrangement indicates a deep, strategic partnership between CDCI and Ajanta Pharma. The stability of this relationship is further evidenced by the consistent number of shipments over the years, suggesting a reliable and ongoing collaboration.

However, this single-source dependency also presents potential risks. Any disruptions in Ajanta Pharma's production or supply chain could directly impact CDCI's ability to meet market demand. To mitigate such risks, it would be prudent for CDCI to consider diversifying its supplier base, thereby enhancing supply chain resilience and reducing potential vulnerabilities.

2Supply Chain Resilience

CDCI's reliance on a single supplier, Ajanta Pharma Ltd., for its pharmaceutical imports from India suggests a concentrated supply chain. While this can lead to streamlined operations and potentially favorable terms, it also exposes the company to risks associated with supplier disruptions. The absence of publicly available information regarding backup suppliers or alternative sourcing strategies indicates a need for CDCI to evaluate and potentially diversify its supply chain to enhance resilience.

Importing Pharmaceuticals into Philippines — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Philippines

1Regulatory Authority & Framework

In the Philippines, the Food and Drug Administration (FDA) is the primary regulatory body overseeing the importation, distribution, and marketing of pharmaceutical products. The FDA ensures that all pharmaceutical products meet the required standards of safety, efficacy, and quality before they are made available to the public.

Key legislation governing pharmaceutical imports includes the FDA Act of 2009, which established the FDA and delineated its responsibilities, and various Implementing Rules and Regulations (IRRs) that provide detailed guidelines for compliance. These regulations cover aspects such as licensing, product registration, and post-marketing surveillance.

2Import Licensing & GMP

To import pharmaceutical products into the Philippines, companies must obtain a License to Operate (LTO) from the FDA, which authorizes them to engage in specific activities such as importing and wholesaling. Additionally, each pharmaceutical product must have a Certificate of Product Registration (CPR), ensuring that the product meets the FDA's standards for safety, efficacy, and quality.

Good Manufacturing Practice (GMP) certification is also a critical requirement. The FDA recognizes GMP certificates from reputable authorities, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). This recognition ensures that imported pharmaceutical products are manufactured in facilities adhering to internationally accepted quality standards.

THE Cathay Drug CO. Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

CDCI's focus on importing antihistamines and respiratory medications aligns with the prevalent health concerns in the Philippines, such as allergies and respiratory conditions. The significant market demand for these therapeutic areas drives the company's import strategy, ensuring that essential medications are readily available to meet the needs of the Filipino population.

2Sourcing Profile

CDCI's sourcing strategy emphasizes the procurement of generic drug formulations, particularly in the antihistamine and respiratory categories. The company's exclusive partnership with Ajanta Pharma Ltd. for these products indicates a strategic approach to ensure consistent quality and supply. India's robust pharmaceutical manufacturing capabilities and adherence to international GMP standards make it a suitable sourcing partner for CDCI's needs.

3Market Positioning

By focusing on essential therapeutic areas such as antihistamines and respiratory medications, CDCI positions itself to serve a broad segment of the Philippine market, including retail pharmacies, hospitals, and government health programs. The company's strategic sourcing and distribution ensure that these critical medications are accessible to various healthcare providers and patients across the country.

Seller's Guide — How to Become a Supplier to THE Cathay Drug CO. Inc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with CDCI by offering complementary products or alternative formulations that align with CDCI's existing portfolio. By diversifying its supplier base, CDCI can enhance its product offerings and mitigate potential risks associated with over-reliance on a single supplier. Indian exporters can explore this opportunity by ensuring their products meet the FDA's regulatory requirements and align with the therapeutic areas of interest to CDCI.

2Requirements & Qualifications

Indian exporters seeking to supply pharmaceutical products to CDCI and the Philippine market must ensure that their products are manufactured in facilities with recognized GMP certifications, such as EU GMP, WHO GMP, or PIC/S. Additionally, products must comply with the FDA's requirements for safety, efficacy, and quality, including obtaining the necessary LTO and CPR. Adherence to labeling requirements in English and Filipino, as well as serialization mandates, is also essential.

3How to Approach

Frequently Asked Questions — THE Cathay Drug CO. Inc

What products does THE Cathay Drug CO. Inc import from India?

THE Cathay Drug CO. Inc imports 2 pharmaceutical products across 2 categories. Top imports: Cetirizine ($700.0K), Montelukast ($700.0K).

Who supplies pharmaceuticals to THE Cathay Drug CO. Inc from India?

THE Cathay Drug CO. Inc sources from 1 verified Indian suppliers. The primary supplier is Ajanta Pharma Limited (100.0% of imports, $1.9M).

What is THE Cathay Drug CO. Inc's total pharmaceutical import value?

THE Cathay Drug CO. Inc's total pharmaceutical import value from India is $1.4M, based on 28 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does THE Cathay Drug CO. Inc focus on?

THE Cathay Drug CO. Inc imports across 2 categories. The largest: Antihistamines & Allergy (50.0%), Respiratory (50.0%).

Get Full THE Cathay Drug CO. Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.